@article{oai:niigata-u.repo.nii.ac.jp:00011484,
 author = {小山, 諭 and 畠山, 勝義},
 issue = {11},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Nov},
 note = {The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. Trastuzumab (Herceptin^[○!R]), a recombinant monoclonal antibody against HER2 has been becoming a key drug for HER2-overexpressed breast cancer, moreover to be used in ajuvant and neoadjuvant settings.},
 pages = {622--625},
 title = {5 乳癌におけるトラスツヅマブ(ハーセプチン^[○!R])療法(シンポジウム がんの分子標的治療, 第628回新潟医学会)},
 volume = {121},
 year = {2007}
}